Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

A Single Center Real-world Observational Study of Response to Dacarbazine or Dacarbazine Combinations in Metastatic Melanoma Refractory to Immunotherapy

Background/Aim: Outcomes in cutaneous melanoma have improved significantly with the introduction of immune checkpoint inhibitors (ICIs). However, a subset of patients remains refractory to ICIs. Dacarbazine is a well-established chemotherapy option for melanoma, and National Institute for Health and Clinical Excellence...

Maleeha Anwar, G. Meléndez-Torres, R. Frazer · 0 citations
Review Open access Aug 2026

IUC26658-92 Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations

An ethnicity-based benchmarking analysis of therapeutic outcomes across standard-of-care ICI combination regimens demonstrates consistent clinical efficacy across Asian and Caucasian populations, with no statistically significant or clinically meaningful divergence in ORR or PFS.

D. Khanna, T. Dey, E. Blanchard-Cavagis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.